19.23
price up icon0.58%   0.11
after-market Handel nachbörslich: 19.30 0.07 +0.36%
loading
Schlusskurs vom Vortag:
$19.12
Offen:
$19.5
24-Stunden-Volumen:
107.26K
Relative Volume:
0.63
Marktkapitalisierung:
$168.35M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-961.50
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
-8.43%
1M Leistung:
+20.87%
6M Leistung:
+62.83%
1J Leistung:
+19.19%
1-Tages-Spanne:
Value
$18.78
$20.00
1-Wochen-Bereich:
Value
$18.54
$21.66
52-Wochen-Spanne:
Value
$6.53
$24.67

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
Firmenname
Seres Therapeutics Inc
Name
Telefon
617 945 9626
Name
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
103
Name
Twitter
@SeresTX
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
MCRB's Discussions on Twitter

Vergleichen Sie MCRB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MCRB
Seres Therapeutics Inc
19.23 167.39M 123.24M 136.00K -148.99M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-08 Herabstufung Chardan Capital Markets Buy → Neutral
2024-10-24 Herabstufung JP Morgan Neutral → Underweight
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-04-21 Eingeleitet JP Morgan Neutral
2021-07-23 Herabstufung Goldman Neutral → Sell
2021-05-18 Fortgesetzt Goldman Neutral
2021-03-05 Hochstufung Chardan Capital Markets Neutral → Buy
2020-09-18 Herabstufung Chardan Capital Markets Buy → Neutral
2020-08-18 Eingeleitet Piper Sandler Overweight
2020-08-11 Bestätigt H.C. Wainwright Buy
2020-08-11 Hochstufung Jefferies Hold → Buy
2019-04-30 Eingeleitet Jefferies Hold
2018-10-22 Eingeleitet Chardan Capital Markets Buy
2017-10-13 Eingeleitet Oppenheimer Outperform
2017-08-04 Bestätigt H.C. Wainwright Buy
2017-02-01 Bestätigt FBR & Co. Outperform
2016-08-12 Bestätigt FBR Capital Outperform
2016-08-01 Herabstufung BofA/Merrill Buy → Neutral
2016-08-01 Bestätigt H.C. Wainwright Buy
2016-07-29 Fortgesetzt H.C. Wainwright Buy
2016-03-30 Eingeleitet FBR Capital Outperform
2016-03-03 Eingeleitet Guggenheim Buy
2016-01-25 Eingeleitet H.C. Wainwright Buy
2015-10-22 Hochstufung BofA/Merrill Neutral → Buy
2015-07-22 Eingeleitet Canaccord Genuity Buy
2015-07-21 Eingeleitet Goldman Neutral
2015-07-21 Eingeleitet Leerink Partners Outperform
Alle ansehen

Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten

pulisher
08:59 AM

How Seres Therapeutics Inc. (1S90) stock moves on employment dataMarket Performance Recap & Stock Timing and Entry Methods - newser.com

08:59 AM
pulisher
08:58 AM

News impact scoring models applied to Seres Therapeutics Inc.CPI Data & Fast Gaining Stock Strategy Reports - newser.com

08:58 AM
pulisher
08:52 AM

Is Seres Therapeutics Inc. stock a contrarian buyAnalyst Downgrade & Weekly Watchlist for Hot Stocks - newser.com

08:52 AM
pulisher
06:13 AM

Vontobel Holding Ltd. Has $892,000 Holdings in Seres Therapeutics, Inc. $MCRB - MarketBeat

06:13 AM
pulisher
Oct 12, 2025

Will Seres Therapeutics Inc. stock benefit from infrastructure spendingMarket Performance Report & High Accuracy Trade Alerts - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Is Seres Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Consistent Profit Trade Alerts - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Seres Therapeutics soars on report of takeover offer - MSN

Oct 12, 2025
pulisher
Oct 11, 2025

Exit strategy if you’re trapped in Seres Therapeutics Inc.Weekly Trading Summary & Expert Verified Movement Alerts - newser.com

Oct 11, 2025
pulisher
Oct 10, 2025

Is Seres Therapeutics Inc. forming a bottoming baseTreasury Yields & Long-Term Growth Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can you recover from losses in Seres Therapeutics Inc.Weekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Quantitative breakdown of Seres Therapeutics Inc. recent moveCPI Data & Stepwise Swing Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace

Oct 10, 2025
pulisher
Oct 10, 2025

Is it too late to sell Seres Therapeutics Inc.2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Seres Therapeutics (NASDAQ:MCRB) Receives "Sell (D+)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Building trade automation scripts for Seres Therapeutics Inc.July 2025 Macro Moves & High Return Trade Opportunity Guides - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Target Price at $14.33 - Defense World

Oct 06, 2025
pulisher
Oct 06, 2025

Technical signs of recovery in Seres Therapeutics Inc.July 2025 Trends & Verified Momentum Watchlists - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Seres Therapeutics Inc. stock retracement – recovery analysisMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

How high can Seres Therapeutics Inc. stock goMarket Activity Summary & Daily Momentum Trading Reports - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 04:28:16 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Understanding Seres Therapeutics Inc.’s price movementJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Seres Therapeutics Inc. a candidate for recovery playJuly 2025 Update & Daily Entry Point Alerts - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Seres Therapeutics announces workforce reduction to extend cash runway - Investing.com

Oct 03, 2025
pulisher
Oct 03, 2025

Seres Therapeutics Cuts Costs to Extend Cash Runway - TipRanks

Oct 03, 2025
pulisher
Oct 03, 2025

Dated alerts on Seres Therapeutics' measures to cut costs withdrawn - MarketScreener

Oct 03, 2025
pulisher
Oct 03, 2025

Developing predictive dashboards with Seres Therapeutics Inc. dataWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Using data tools to time your Seres Therapeutics Inc. exit2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Published on: 2025-10-03 00:05:20 - newser.com

Oct 03, 2025
pulisher
Oct 01, 2025

Is Seres Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Outperform the Market with Aggressive Picks - earlytimes.in

Oct 01, 2025
pulisher
Oct 01, 2025

Goldman Sachs Group Inc. Acquires 21,679 Shares of Seres Therapeutics, Inc. $MCRB - MarketBeat

Oct 01, 2025
pulisher
Sep 29, 2025

What analysts say about Seres Therapeutics Inc stockInstitutional Holding Changes & Capitalize On Fast Trends - earlytimes.in

Sep 29, 2025
pulisher
Sep 27, 2025

What drives Seres Therapeutics Inc stock priceMoving Average Crossovers & Master Technical Analysis With Free Tools - earlytimes.in

Sep 27, 2025
pulisher
Sep 27, 2025

What earnings revisions data tells us about Seres Therapeutics Inc.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Using portfolio simulators with Seres Therapeutics Inc. includedPortfolio Return Report & Consistent Income Trade Ideas - newser.com

Sep 26, 2025

Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):